


An alphavirus virus like particle (VLP) vaccine and a platform



Recent outbreak of Chikungunya virus (CHIKV), a mosquito-borne alphavirus appeared on Reunion Island in 2005 and has spread to more than 20 countries including 2013 outbreak in the Caribbean. Infection by CHIKV in humans is characterized by rash, high fever and, its hallmark feature, severe arthritis that can persist for years. The dissemination of this epidemic virus is associated with genetic mutations that facilitated its adaptation to a new insect vector, the Asian tiger mosquito, *Aedes albopictus* which survives in temperate climates and is widely distributed. CHIKV continues to cause substantial morbidity and vaccine development remains a high priority. In this talk, CHIKV VLP vaccine development (Akahata W, et al. 2010, Nat Med) and a platform technology of the alphavirus VLP to apply to other vaccine developments will be presented.

Date : 平成26年7月23日(水) (Wednesday, July 23)

Time : 16 : 30 ~ 17 : 30 Language : English

Place : 長崎大学熱帯医学研究所 大会議室

Main Conference Room, 1F,

Nagasaki University Institute of Tropical Medicine

Lecturer : 赤畑 渉 Wataru Akahata, Ph.D.
Co-founder and Chief Executive Officer
VLP Therapeutics



Profile:

Kyoto University Graduate School

NIH Vaccine Research Center, Senior Scientist

VLP Therapeutics, Co-founder and Chief Executive officer